Aptamer-Targeted Drug Delivery for Staphylococcus aureus Biofilm

Ommen, Pernille; Hansen, Line Block; Hansen, Bente K.; Vu-Quang, Hieu; Kjems, Jørgen

doi:10.3389/fcimb.2022.814340

Cited by 26 publications

(19 citation statements)

References 49 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibiofilm activity assay of six types of aptamers against E. coli EPEC K1.1 showed different activities [33]. Investigate of six DNA aptamers bound to S. aureus cells in the biofilm showed one aptamer that could facilitate the accumulation of liposomes around S. aureus cells inside the biofilm [58].…”

Section: Discussionmentioning

confidence: 99%

Antibiofilm Activity and Binding Specificity of Polyclonal DNA Aptamers on Staphylococcus aureus and Escherichia coli

Kusumawati

Mustopa²,

Umami³

et al. 2022

Microbiol. Biotechnol. Lett.

View full text Add to dashboard Cite

Aptamers are short, chemically synthesized, single-stranded DNA or RNA oligonucleotides that fold into unique three-dimensional structures. In this study, we aim to determine the antibiofilm activity and binding specificity of the six polyclonal DNA aptamers (S15K3, S15K4, S15K6, S15K13, S15K15, and S15K20) on Staphylococcus aureus BPA-12 and Escherichia coli EPEC 4. Aptamer S15K6 showed the highest percentage of antibiofilm activity against S. aureus BPA-12 (37.4%) as shown by the lowest OD 570 value of 0.313. Aptamer S15K20 showed the highest percentage of antibiofilm activity against E. coli EPEC 4 (15.4%) as shown by the lowest OD 570 value of 0.515. Aptamers S15K13 and S15K20 showed antibiofilm activities against both S. aureus BPA-12 and E. coli EPEC4, and thus potentially have broad reactivity. Furthermore, based on the binding capacity and Kd values from our previous study, the binding specificity assay of selected polyclonal DNA aptamers (S15K3 and S15K15) against S. aureus BPA-12, E. coli EPEC 4, S. aureus BPA-6, S. agalactiae, E. coli MHA-6, and Listeria monocytogenes were performed using qPCR. Aptamers S15K3 and S15K15 showed specific binding to S. aureus BPA-12, E. coli EPEC 4, S. aureus BPA-6, and S. agalactiae, but could not bind to E. coli MHA-6 and L. monocytogenes. Therefore, this study showed that the polyclonal DNA aptamers have antibiofilm activity and were able to bind to S. aureus BPA-12 and E. coli EPEC 4 bacteria.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibiofilm Activity and Binding Specificity of Polyclonal DNA Aptamers on Staphylococcus aureus and Escherichia coli

Kusumawati

Mustopa²,

Umami³

et al. 2022

Microbiol. Biotechnol. Lett.

View full text Add to dashboard Cite

show abstract

“…As such, aptamers against S. aureus surface proteins, such as staphylococcal protein A are a promising means to uniquely target proteins expressed exquisitely on the surface of S. aureus biofilms. Recently, rifampicin and vancomycin were loaded into liposomes and conjugated to S. aureus surface targeting aptamers towards S. aureus biofilm eradication [ 128 ]. These successfully accumulated around S. aureus cells in biofilms, while the liposomes penetrated the biofilm and released sufficient levels of antimicrobial cargoes to eradicate S. aureus biofilms in vitro.…”

Section: Antimicrobials and Anti-biofilm Strategiesmentioning

confidence: 99%

Strategies to Mitigate and Treat Orthopaedic Device-Associated Infections

et al. 2022

View full text Add to dashboard Cite

Orthopaedic device implants play a crucial role in restoring functionality to patients suffering from debilitating musculoskeletal diseases or to those who have experienced traumatic injury. However, the surgical implantation of these devices carries a risk of infection, which represents a significant burden for patients and healthcare providers. This review delineates the pathogenesis of orthopaedic implant infections and the challenges that arise due to biofilm formation and the implications for treatment. It focuses on research advancements in the development of next-generation orthopaedic medical devices to mitigate against implant-related infections. Key considerations impacting the development of devices, which must often perform multiple biological and mechanical roles, are delineated. We review technologies designed to exert spatial and temporal control over antimicrobial presentation and the use of antimicrobial surfaces with intrinsic antibacterial activity. A range of measures to control bio-interfacial interactions including approaches that modify implant surface chemistry or topography to reduce the capacity of bacteria to colonise the surface, form biofilms and cause infections at the device interface and surrounding tissues are also reviewed.

show abstract

“…153,154 Such as the aptamer-targeted liposome drug delivery system has been successfully customized for the treatment of Staphylococcus aureus biofilm infection. 155 It's noteworthy that the large-scale commercial synthesis of aptamers is remarkably expensive. Hence, the majority of researches on aptamers were merely completed in laboratories.…”

Section: Challeng E S Of Ap Tamer Appli C Ati On Smentioning

confidence: 99%

“…But the systems of aptamers are considered as an effective tool for the treatment of microbial infections, with good anti‐biofilm and antibacterial activities; they can reduce or inhibit the effect of bacterial toxins, and can also be used in drug delivery systems 153,154 . Such as the aptamer‐targeted liposome drug delivery system has been successfully customized for the treatment of Staphylococcus aureus biofilm infection 155 …”

Section: Challenges Of Aptamer Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Aptamers: A prospective tool for infectious diseases diagnosis

Chen

Zhou

Peng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

It is well known that people's health is seriously threatened by various pathogens (such as Mycobacterium tuberculosis, Treponema pallidum, Novel coronavirus, HIV, Mucor, etc.), which leads to heavy socioeconomic burdens. Therefore, early and accurate pathogen diagnosis is essential for timely and effective therapies. Up to now, diagnosing human contagious diseases at molecule and nano levels is remarkably difficult owing to insufficient valid probes when it comes to determining the biological markers of pathogens. Aptamers are a set of high‐specificity and high‐sensitivity plastic oligonucleotides screened in vitro via the selective expansion of ligands by exponential enrichment (SELEX). With the advent of aptamer‐based technologies, their merits have aroused mounting academic interest. In recent years, as new detection and treatment tools, nucleic acid aptamers have been extensively utilized in the field of biomedicine, such as pathogen detection, new drug development, clinical diagnosis, nanotechnology, etc. However, the traditional SELEX method is cumbersome and has a long screening cycle, and it takes several months to screen out aptamers with high specificity. With the persistent development of SELEX‐based aptamer screening technologies, the application scenarios of aptamers have become more and more extensive. The present research briefly reviews the research progress of nucleic acid aptamers in the field of biomedicine, especially in the diagnosis of contagious diseases.

show abstract

Aptamer-Targeted Drug Delivery for Staphylococcus aureus Biofilm

Cited by 26 publications

References 49 publications

Antibiofilm Activity and Binding Specificity of Polyclonal DNA Aptamers on Staphylococcus aureus and Escherichia coli

Antibiofilm Activity and Binding Specificity of Polyclonal DNA Aptamers on Staphylococcus aureus and Escherichia coli

Strategies to Mitigate and Treat Orthopaedic Device-Associated Infections

Aptamers: A prospective tool for infectious diseases diagnosis

Contact Info

Product

Resources

About